Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
QuintilesIMS
Cipla
Merck
Moodys
Cantor Fitzgerald
US Department of Justice
Express Scripts
Argus Health
UBS

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,476,279

« Back to Dashboard

Which drugs does patent 8,476,279 protect, and when does it expire?

Patent 8,476,279 protects TRINTELLIX and is included in one NDA.

This patent has seventy patent family members in thirty-six countries.
Summary for Patent: 8,476,279
Title:Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Abstract: The invention provides compounds represented by the general formula I ##STR00001## wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
Inventor(s): Bang-Andersen; Benny (Copenhagen S, DK)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:13/367,065
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 8,476,279

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Sign Up
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-002 Sep 30, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Sign Up
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-003 Sep 30, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Sign Up
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-004 Sep 30, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,476,279

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2001 01466Oct 04, 2001

Non-Orange Book US Patents Family Members for Patent 8,476,279

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,138,407 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Sign Up
7,683,053 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Sign Up
8,110,567 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Sign Up
9,708,280 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Sign Up
9,090,575 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Sign Up
7,144,884 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Sign Up
7,148,238 Phenyl-piperazine derivatives as serotonin reuptake inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,476,279

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 036659 ➤ Sign Up
Argentina 066460 ➤ Sign Up
Austria 386730 ➤ Sign Up
Austria 441631 ➤ Sign Up
Australia 2002333220 ➤ Sign Up
Australia 2006215994 ➤ Sign Up
Brazil 0212733 ➤ Sign Up
Brazil 122012023120 ➤ Sign Up
Canada 2462110 ➤ Sign Up
China 1319958 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Covington
Chubb
Johnson and Johnson
Chinese Patent Office
Daiichi Sankyo
Colorcon
McKinsey
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot